InsiderTrades.com logo
Exposed: 10 CENT Crypto to Explode April 20th?
From True Market Insiders   |   Ad
The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…
Click For My #1 FREE Crypto for 2024
Alan Glicklich net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Alan Glicklich Biography and Net Worth

Insider of Chinook Therapeutics
Alan is the Chief Medical Officer at Chinook Therapeutics. Prior to Chinook, Alan was Chief Medical Officer at Bird Rock Bio, a San Diego based biotechnology company focused on clinical development of monoclonal antibodies. Before that, Alan was VP of clinical development at Arena Pharmaceuticals. Prior to Arena he was VP of clinical affairs at Savient pharmaceuticals and Veloxis Pharmaceuticals. Alan has also served in senior clinical roles at Mitsubishi-Tanabe Development America, Bristol Myers Squibb, Sanofi-Aventis and Regeneron. Alan has a medical degree from the University of Wisconsin, an MBA from Emory University, and a BA in biology from the University of Chicago.

What is Alan Glicklich's net worth?

The estimated net worth of Alan Glicklich is at least $807,800.00 as of June 16th, 2021. Dr. Glicklich owns 20,000 shares of Chinook Therapeutics stock worth more than $807,800 as of April 26th. This net worth estimate does not reflect any other assets that Dr. Glicklich may own. Learn More about Alan Glicklich's net worth.

How old is Alan Glicklich?

Dr. Glicklich is currently 60 years old. There are 4 older executives and no younger executives at Chinook Therapeutics. The oldest executive at Chinook Therapeutics is Mr. Eric H. Bjerkholt M.B.A., Chief Financial Officer, who is 63 years old. Learn More on Alan Glicklich's age.

How do I contact Alan Glicklich?

The corporate mailing address for Dr. Glicklich and other Chinook Therapeutics executives is 740 HEINZ AVENUE, BERKELEY CA, 94710. Chinook Therapeutics can also be reached via phone at (206) 485-7241 and via email at [email protected]. Learn More on Alan Glicklich's contact information.

Has Alan Glicklich been buying or selling shares of Chinook Therapeutics?

Alan Glicklich has not been actively trading shares of Chinook Therapeutics during the last ninety days. Most recently, Alan Glicklich sold 20,000 shares of the business's stock in a transaction on Wednesday, June 16th. The shares were sold at an average price of $16.35, for a transaction totalling $327,000.00. Following the completion of the sale, the insider now directly owns 20,000 shares of the company's stock, valued at $327,000. Learn More on Alan Glicklich's trading history.

Who are Chinook Therapeutics' active insiders?

Chinook Therapeutics' insider roster includes Srinivas Akkaraju (Director), Eric Bjerkholt (CFO), Jerel Davis (Director), Eric Dobmeier (CEO), Tom Frohlich (COO), Alan Glicklich (Insider), and Andrew King (Insider). Learn More on Chinook Therapeutics' active insiders.

Are insiders buying or selling shares of Chinook Therapeutics?

In the last twelve months, insiders at the sold shares 2 times. They sold a total of 2,323 shares worth more than $72,498.54. The most recent insider tranaction occured on August, 1st when insider Andrew James King sold 1,168 shares worth more than $45,587.04. Insiders at Chinook Therapeutics own 16.8% of the company. Learn More about insider trades at Chinook Therapeutics.

Information on this page was last updated on 8/1/2023.

Alan Glicklich Insider Trading History at Chinook Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/16/2021Sell20,000$16.35$327,000.0020,000View SEC Filing Icon  
See Full Table

Alan Glicklich Buying and Selling Activity at Chinook Therapeutics

This chart shows Alan Glicklich's buying and selling at Chinook Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Chinook Therapeutics Company Overview

Chinook Therapeutics logo
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington. As of August 11, 2023, Chinook Therapeutics, Inc. operates as a subsidiary of Novartis AG.
Read More

Today's Range

Now: $40.39
Low: $40.39
High: $40.39

50 Day Range

MA: $39.86
Low: $38.66
High: $40.39

2 Week Range

Now: $40.39
Low: $18.34
High: $40.51

Volume

N/A

Average Volume

1,186,257 shs

Market Capitalization

$2.90 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.34
These AI trades triggered this morning (545% return)
From Prosper Trading Academy   |   Ad
If you think a market crash is possible in 2024, I don't know why you're not using this yet.
Click Here To Get Your Free Copy